Between tirzepatide and semaglutide, the honest starting point is that both work, both are hard to tolerate at first, and the one head-to-head trial gave tirzepatide the edge on average weight loss. That single fact does not settle a personal choice. What settled it here was cost, side effect history, and which dosing rhythm fit an actual week. This is how one reader weighed tirzepatide vs semaglutide and decided which to ask a prescriber for, and what would push the answer the other way.
What does the head-to-head trial actually show?
Most comparisons online stitch together separate trials, which is misleading because those studies enrolled different people under different rules. There is one direct comparison worth leaning on. In a 2024 randomized study published in JAMA Internal Medicine comparing semaglutide and tirzepatide for weight loss, tirzepatide produced greater average reduction. That result is real, and it is why tirzepatide gets talked about as the stronger option.
The context around it matters. Tirzepatide’s own obesity trial, SURMOUNT-1, published in 2022, showed large average losses across doses, and SURMOUNT-CN in Chinese adults pointed the same direction in a different population. On the semaglutide side, the STEP 8 trial compared weekly semaglutide against daily liraglutide and favored semaglutide. These are strong drugs. The gap between them is smaller than the gap between either drug and doing nothing.
What happens when you stop, and why it mattered to me
Both medicines share an uncomfortable trait: stopping tends to reverse the benefit. In the STEP 4 semaglutide trial, people switched to placebo regained weight, while those who continued kept losing. The tirzepatide maintenance study, SURMOUNT-4, told the same story: continued treatment held the loss, withdrawal gave much of it back.
That reframed the decision. This is not a short course. Whichever molecule wins on paper, the real question is which one a person can sustain for years, which pulled the choice back toward cost and tolerability rather than the trial headline.
Are the side effects really different?
Not in kind. Both are gastrointestinal in their downside: nausea, diarrhea, constipation, vomiting, mostly during the weeks when the dose steps up. The prescribing information for both tirzepatide brands, the Zepbound label for weight management and the Mounjaro label for type 2 diabetes, lists the same class-level warnings you would expect, including a boxed thyroid tumor warning seen across this drug family. The lesson is that a bad first month is common with either, and slow titration matters more than brand.
Does a related condition change the answer?
Sometimes, and this is where tirzepatide has extra evidence. A 2024 study found tirzepatide reduced obstructive sleep apnea severity in people with obesity, and tirzepatide is also sold in a diabetes form. If sleep apnea or blood sugar is part of the picture, a prescriber may reasonably lean toward tirzepatide for reasons that have nothing to do with the weight-loss average. For someone without those conditions, that particular tiebreaker disappears.
How do the cost routes compare?
| Route | What sets the price | Main limitation |
|---|---|---|
| Covered benefit | Formulary tier, deductible, coinsurance | Requires the plan to cover weight management |
| Manufacturer savings card | Commercial insurance status and eligibility | Usually excludes government insurance |
| Manufacturer self-pay | Fixed cash price set by the maker | Refill timing and dose conditions |
| Compounded medication | Pharmacy and provider pricing | Not an FDA-approved product |
This table did most of the deciding. Coverage is usually a category decision, so if a plan excludes anti-obesity medication, it excludes both molecules together and switching between them fixes nothing. That pushes many people into self-pay, where the comparison stops being about milligrams and starts being about what a sustainable monthly number looks like.
Where does compounded medication fit?
Compounded semaglutide and tirzepatide are prepared by compounding pharmacies rather than made under an approved application, so they are not FDA-approved products and have not been through the process behind the trials cited above. That is a genuine distinction, not a formality. What they tend to offer is a flat monthly cash price. Named telehealth practices in the field, including Ro, Hims and Hers, Henry Meds, and LillyDirect, sit at different points on price and product type, and one useful independent breakdown of how tirzepatide and semaglutide compare can help before a prescriber conversation about which route makes sense. Prescribing there is handled by a licensed clinician, not sold as an off-the-shelf product.
Whether the compounded trade, less regulatory assurance for a predictable price, is reasonable depends on the person. It is a conversation for a prescriber who knows the case, not a default.
So which did I decide to ask for?
Tirzepatide, for a specific reason: the direct trial favored it, and the self-pay math in this case came out close enough that the stronger average was worth asking about first. If the tolerability had been rough, or if only semaglutide were covered, the plan was to switch without treating it as a downgrade. The evidence for semaglutide is strong and long-running, and the better molecule is the one a person can actually stay on.
Key takeaways
- One direct trial favored tirzepatide for weight loss, but the margin is smaller than the difference from no treatment.
- Both regain weight after stopping, so long-term affordability outweighs a small average gap.
- Side effects are similar and class-driven; slow titration matters more than brand.
- Tirzepatide has extra evidence in sleep apnea and a diabetes form, which can tip a prescriber’s choice.
- Coverage is usually a category decision, so a brand swap rarely resolves a denial.
See also: Understanding Child Custody Law in NSW
Frequently asked questions
Does tirzepatide always beat semaglutide?
In the one head-to-head trial that compared them for weight loss, tirzepatide produced greater average reduction. Averages are not individuals, though, and tolerability, cost, and access often decide the real outcome more than a percentage point on a chart.
Are the side effects different between the two?
They are broadly similar. Both commonly cause nausea, diarrhea, constipation, and vomiting, usually worst during dose increases. The pattern is more about the drug class than about which of the two a person takes.
Is one better if I have sleep apnea or diabetes?
Tirzepatide has trial evidence in obstructive sleep apnea and is approved in a diabetes form. If a related condition is part of the picture, that evidence can tip a prescriber toward it, but the decision belongs with them.
Is compounded tirzepatide or semaglutide the same as the brand?
No. Compounded versions are prepared by compounding pharmacies and are not FDA-approved products. They may use the same active molecule but have not gone through the approval process behind the published brand trials.
What should I settle before choosing between them?
Whether either is covered, what each self-pay route costs, and which side effect and dosing pattern fits your life. Those answers usually matter more than the small average difference between the two molecules.
